OCGN

• Clinical Differentiation for OCU410ST (Stargardt Disease):
  • The company's Phase 2-3 Guardian trial includes patients aged 3 years and older, while competitor trials focus on patients 12 years and older, allowing access to the earlier-stage pediatric population where treatment is more impactful for this progressive degenerative disease
  • The trial enrolls a broader population, including patients from early to late stage Stargardt disease, with a wider range of lesion sizes (both smaller and larger lesions) than competing trials, and includes all ABCA4 mutation variants linked to the condition
  • Published Phase 1 data demonstrated slowed disease progression, and observed functional improvements: treated patients gained an average of six letters (nearly one line) of visual acuity compared to untreated eyes
• Pivotal Armada 3 (Geographic Atrophy) Trial Status:
  • The Phase 3 trial protocol and 237-patient sample size were aligned with the FDA, based on strong effect size data from the earlier Armada 1 Phase 1-2 trial; the 237-patient size delivers 95% power for the trial, with 2:1 randomization (158 treatment, 79 control)
  • FDA clearance has been received to initiate the Phase 3 trial in the coming weeks
• CMC and Manufacturing Progress:
  • The company is ahead of schedule on manufacturing process performance qualification (PPQ), producing commercial-scale batches during Phase 3 development, unlike many competing gene therapy programs that face CMC delays

• Cash runway is currently sufficient to support operations into 2028, enabling execution of all late-stage clinical programs
• BLA submission for OCU410 (for retinitis pigmentosa) and OCU410ST (for Stargardt disease) is on track to be completed in the second quarter of 2027, with a potential approval in the fourth quarter of 2027 via the 6-month accelerated PDUFA review timeline
• Commercial launch of OCU400 is targeted for the end of 2027, following approval
• Rolling BLA submission will proceed per FDA guidance: non-clinical and CMC modules will be filed after top-line trial data and a pre-BLA meeting, with the 6-month PDUFA clock starting only after the full BLA (including the clinical module) is submitted

No financial segment performance data or numerical revenue/performance figures for product segments were disclosed in the provided transcript.

No explicit risks or operational failures were discussed in the provided transcript excerpt.

Q: Can you address the potential for disease reversal and visual acuity improvement in the ongoing OCU410ST Phase 2-3 trial, and how patient entry criteria were structured?

A: The trial enrolled a far broader patient population than competitors, including patients as young as 3 years old (vs 12+ for competitors), all stages of disease, a wider range of lesion sizes, and all ABCA4 mutation variants. Phase 1 data already confirmed slowed progression, and observed functional gains of ~6 letters of visual acuity in treated patients relative to controls, making improvement a plausible upside outcome. The trial's primary endpoint is lesion change over 1 year, with visual acuity measured as a secondary endpoint, and long-term follow-up data from Phase 1 patients will also be available for the BLA.

Q: How is the company managing cash, and what tradeoffs would it make between clinical trial initiation and commercial preparation if additional capital was needed?

A: The company currently has sufficient cash to reach 2028, enough to complete all planned trials and reach BLA submission in 2027. Management prioritizes minimizing shareholder dilution, but is evaluating both non-dilutive and dilutive options to extend runway if needed. Key non-dilutive options include selling the PRV voucher obtained for the OCU410ST rare disease designation, which could fetch 100 million to 200 million dollars even prior to approval, as well as potential business development deals.

Q: Why was the Armada 3 Phase 3 trial sample size reduced from the previously planned 300 patients to 237, and was this change aligned with the FDA?

A: The change was fully discussed and aligned with the FDA. The original 300-patient estimate was preliminary, but after observing a strong 31% reduction in progression with the selected medium optimal dose in the earlier Phase 1-2 trial, the sample size calculation was updated. 237 total patients randomized 2:1 to treatment vs control provides 90%+ statistical power for the trial's primary endpoint, so no reduction in trial power resulted from the change.

Q: Why was the rolling BLA submission rescheduled from the third quarter to after top-line limelight data in the first quarter, and does this change the overall approval timeline?

A: The company is already ready to submit CMC and non-clinical modules, but the FDA requested the adjusted timeline to accommodate their internal workload. This change does not alter the overall approval timeline. The 6-month accelerated PDUFA clock only starts once the full BLA (including the clinical module) is submitted, which remains on track for the second quarter of 2027, with approval still expected in the fourth quarter of 2027.